Roland Humm

USPTO Granted Patents = 15 (Patent Applications = 9)

CIPO Patents = 1

EPO Patents = 5 (Patent Applications = 7)

Average Co-Inventor Count = 5.0

ph-index = 2

Forward Citations = 18(Granted Patents)

Location History:

Riehen, CH (2003)
Freiburg, DE (2004 - 2008)
Basel, CH (2019)
Auggen, DE (2009 - 2022)

Company Filing History:

13 out of 4,945

Hoffmann-la Roche Inc.

Basilea Pharmaceutica Ag

patents

4. 1 out of 832,843

Other

patents

where one patent can have more than one assignee

Years Active: 2003-2025

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12344614 - Benzodiazepine derivatives as GABA a GAMMA1 PAM (2025-07-01),

2. 11447478 - BACE1 inhibitors (2022-09-20),

3. 10457667 - Indolin-2-one derivatives (2019-10-29),

4. 10377746 - Indolin-2-one derivatives (2019-08-13),

5. 9988390 - Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease (2018-06-05),

6. 9067926 - Fluoromethyl-5,6-dihydro-4H-[1,3]OXAZINES (2015-06-30),

7. 8815881 - 1,4,5,6-tetrahydro-pyrimidin-2-ylamine compounds (2014-08-26),

8. 8673894 - 2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine or 2,3,6,7-tetrahydro-[1,4]oxazepin-5-ylamine compounds (2014-03-18),

9. 8461160 - Dihydropyrimidinones (2013-06-11),

10. 8404680 - N-[3-(5-amino-3,3a,7,7a-tetrahydro-1H-2,4-dioxa-6-aza-inden-7-yl)-phenyl]-amides as BACE1 and/or BACE2 inhibitors (2013-03-26),

11. 7501413 - Dicarboxamide derivatives (2009-03-10),

12. 7345082 - Phosphinic acids (2008-03-18),

13. 6890947 - Indolyl derivatives (2005-05-10),

14. 6747049 - Oxazole derivatives (2004-06-08),

15. 6504025 - Process for the preparation of vinyl-pyrrolidinone cephalosporin derivatives (2003-01-07),

Sure, I can help you with that! Here is an article about inventor Roland Humm:

Title: The Innovative Journey of Roland Humm

Introduction:

Roland Humm is a talented inventor hailing from Auggen, Germany, who has made significant contributions in the field of pharmaceuticals with a total of 14 patents to his name.

Latest Patents:

Among his latest patents is the development of BACE1 inhibitors, compounds that exhibit inhibitory activity against BACE1, showing promise in the therapeutic treatment of Alzheimer's disease. Additionally, he has also worked on indolin-2-one derivatives, which have potential applications in the treatment of a wide range of CNS diseases, from schizophrenia to Alzheimer's and even cardiovascular disorders.

Career Highlights:

Throughout his career, Roland Humm has proven to be an invaluable asset to renowned companies such as Hoffmann-la Roche Inc. and Siena Biotech S.p.a.. His innovative spirit and dedication have led to the successful development of groundbreaking pharmaceutical compounds.

Collaborations:

In his journey of invention, Roland Humm has collaborated closely with esteemed colleagues such as Hans Hilpert and Thorsten Muser. Together, they have pushed the boundaries of pharmaceutical research and development, bringing forth new solutions to complex medical challenges.

Conclusion:

In conclusion, Roland Humm stands as a beacon of innovation in the pharmaceutical industry, with his prolific patent portfolio and groundbreaking discoveries paving the way for advancements in treating various CNS diseases. His collaborations and career highlights reflect a passion for transformative research that continues to impact the field positively.Dot

This text is generated by artificial intelligence and may not be accurate.